the Company's ability to continue as a going concern.

Acasti will immediately begin the process of recruiting new directors and expects to regain compliance with Nasdaq Listing Rule 5605 and National Instrument 52-110 of the Canadian securities regulators, which require a company’s audit committee to be comprised of at least three independent directors, within six months and in any event prior to Acasti’s next annual shareholders’ meeting.

We expect to continue advancing our potential best-in-class prescription omega-3 product for the treatment of severe hypertriglyceridemia through the patient enrollment process in 2018, and beyond to expected top line results by the end of 2019

We also entered into a non-binding term sheet agreement this quarter with a leading Chinese pharmaceutical company for the development and commercialization of CaPre in certain Asian countries. This partnership is the first step in our worldwide strategy to maximize the value of our asset.

Financing completed to support CaPre Phase 3 trials

The first clinical sites were activated and patient enrollment initiated for the CaPre Phase 3 program

Progressed commercialization agreement with leading Chinese pharmaceutical partner

In both Phase 2 clinical trials, CaPre significantly lowered TGs in patients with mild to severe HTG. Importantly, in these studies, CaPre also demonstrated no deleterious effect on LDL-C (unlike Lovaza and Epanova, which have been shown to significantly increase LDL-C in patients with severe HTG). Further, these Phase 2 data indicated that CaPre may actually reduce LDL-C. LDL-C is undesirable because it accumulates in the walls of blood vessels, where it can cause blockages (atherosclerosis). In the Phase 2 trials, CaPre also reduced non-HDL-C (all cholesterol contained in the bloodstream except HDL-C), which is also considered to be a marker of cardiovascular disease. The COLT trial data showed a mean increase of 7.7% in HDL-C with CaPre at 4 grams per day (p=0.07).

The Company believes that these potential multiple cardiovascular benefits, if confirmed in its Phase 3 program, could be significant differentiators for CaPre in the marketplace, as no currently approved OM3 drug has shown an ability to positively modulate these four major blood lipid categories (TGs, non-HDL-C, LDL-C and HDL-C) in the treatment of severe HTG. Acasti also believes that if supported by additional clinical trials, CaPre has the potential to become a best-in-class OM3 compound for the treatment of patients with high TGs.

trying to create a hype based on wishfull thinking.

$ACST explains new deal being worked out with Chinese pharma partner that CEO Jan D’Aluise called attractive to investors and the first of many more to come #BTS18

$ACST milestones for 2017 include a $10 million round of public offering in December. Most crucial the company obtained their phase 3 plan from the FDA for CaPre treating HTG #BTS18

LAVAL, QUÉBEC--(Marketwired - Jan. 4, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the granting of a patent by the South Korean Patent Office and the granting of a corresponding patent by the Canadian Intellectual Property Office, further strengthening the international intellectual property position of CaPre.
The granted patents are valid until 2030 and relate to a concentrated phospholipid composition and method of using same for treating or preventing disorders associated with cardiovascular diseases. These patents add to Acasti's growing portfolio of issued patents in the United States, Taiwan, Australia, China, Japan, Mexico and Panama. Patent applications with similar claims are being pursued in several other jurisdictions.
"The granting of these additional patents further increase the global commercial opportunities for CaPre," highlighted Pierre Lemieux, Ph.D, Acasti's chief operating officer. "Both patents strengthen the competitive barriers for CaPre and provide market access to the Canadian and South Korean pharmaceutical territories, both of which have strong commercial potential for CaPre."